Progesterone - TherapeuticsMD

Drug Profile

Progesterone - TherapeuticsMD

Alternative Names: TX-002HR; TX-005HR; TX-007HR; TX-12-002HR

Latest Information Update: 16 Sep 2016

Price : $50

At a glance

  • Originator TherapeuticsMD
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Amenorrhoea

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Amenorrhoea in USA (Transdermal) (TherapeuticsMD pipeline, August 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2014 TherapeuticsMD terminates the phase III SPRY trial in Amenorrhoea in USA (NCT02019589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top